A pharmaceutical composition for treating organ fibrosis, its preparation method and application

Abstract

The invention provides a pharmaceutical composition for treating organ fibrosis. The pharmaceutical composition is an agent prepared from the following raw material medicines in parts by weight: 7-13 parts of ephedra, 7-13 parts of almond, 15-20 parts of caulis bambusae in taeniam, 10-15 parts of scutellaria baicalensis, 10-15 parts of the root bark of white mulberry, 6-10 parts of ginseng, 15-20 parts of astragalus, 15-20 parts of the root of red-rooted salvia, 10-15 parts of Chinese angelica, 2-4 parts of crocus sativus, 6-10 parts of ligusticum wallichii, 15-20 parts of radix ophiopogonis, 15-20 parts of asparagus fern, 15-20 parts of the root of straight ladybell and 4-6 parts of liquorice. The invention also provides a preparation method and application of the pharmaceutical composition. According to monarch, ministerial and adjuvant drugs, the various medicines are clear in functions and supplement with one another, the essence of embattled speculative scientific research methodology in a compound compatibility medicine unique in traditional Chinese medicine is fully exerted, the effects of stopping asthma, dredging collaterals and strengthening healthy energy can be achieved, the composition has a good treatment effect on'excessive superficial and deficient root' special syndrome types of pulmonary fibrosis in the formula, and a novel choice is provided for clinical medication.

Description

technical field [0001] The invention relates to a pharmaceutical composition for treating organ fibrosis, a preparation method and application thereof. Background technique [0002] Pulmonary fibrosis (Pulmonary fibrosis / PF) is a disease caused by various causes of lung inflammation, continuous alveolar damage and repeated destruction, repair, reconstruction and excessive deposition of extracellular matrix (Extracellular matrix / ECM), resulting in normal lung tissue structure A disease spectrum characterized by changes and loss of function, which is the common outcome of chronic lung diseases caused by a variety of causes, and is the main pathological basis of respiratory failure. Its etiology and pathogenesis are complex. The regulation of various cytokines and their networks is an extremely important factor in the pathological mechanism of its occurrence and development. [0003] Pulmonary fibrosis belongs to a class of refractory and serious diseases that have attracted a...

AI Technical Summary

Problems solved by technology

[0005] Although pulmonary fibrosis is reversible in treatment, there is still a lack of satisfactory prevention and treatment methods of western medicine, which may be related to the multiple factors of pulmonary fibrosis, multiple targets of disease, and the diversity of pathological processes.

Images